Nigeria is Africa's most populous nation, with approximately 189 million people. Modern contraceptive services are underutilized in Nigeria, which has a modern contraceptive prevalence rate (mCPR) of 10 percent. The country's low mCPR highlights the need for innovative programs to increase women's access to contraceptive services.
In Nigeria, overall modern contraceptive use is very low, with just 10 percent of currently married women using a modern method. However, 60 percent of modern contraceptive services are obtained from private providers, including Patent and Proprietary Medicine (PPM) shops, which provide more than half of these private sector services. PPM shops are owned by Patent and Proprietary Medicine Vendors (PPMVs) licensed to sell patent or proprietary drugs. PPMVs sell a range of contraceptives including condoms, emergency contraceptive pills, refills of oral contraceptive pills, and intrauterine devices (with a referral).
Injectable contraception is the most popular modern method in Nigeria, used by more than 30 percent of currently married modern contraceptive users. Current regulations do not permit PPMVs to sell or administer injectable contraceptives because they are not regarded as sufficiently trained to initiate hormonal contraceptives or to provide any type of injection. Instead, they can only refer clients to health facilities. Nevertheless, almost 13 percent of injectables are provided by PPM shops, according to the 2013 DHS.
Given this, it is an opportune time to generate evidence that can drive policy action to formally engage and train PPMVs in the provision of high quality progestin-only injectable contraceptive services as a key strategy to increase women's access to contraception.
STUDY OBJECTIVES
The Evidence Project, in collaboration with the Federal Ministry of Health (FMOH), is conducting implementation research to:
1. Demonstrate the feasibility of PPMVs administering all forms of progestin-only injectable contraceptives, such as Depo Provera and Sayana® Press. 2. Understand women's experiences using progestin-only injectable contraceptives, including the quality of care they receive when accessing services from PPMVs.
The FMOH also asked the Evidence Project to develop and coordinate training of PPMVs so that they have the necessary skills and information to sell, counsel, and refer for all contraceptive methods, as well as administer progestin-only injectable contraceptives.
The study is taking place in two phases. Phase one (November 2015 to December 2016) was carried out in two states representing two geopolitical zones: Oyo in the south-west and Nasarawa in north-central Nigeria. In each state, four Local Government Areas (LGAs) were selected as study sites (two urban and two rural) for a total of eight LGAs. Phase two began in May 2017 at the request of and with funding from USAID/Nigeria to generate similar evidence from states, selected in consultation with local stakeholders, in the remaining four geopolitical zones, so that the evidence is nationally representative. The phase two study states include: Kaduna (north-west region), Ebonyi (south-east region), Cross River (south-south region), and Bauchi (north-east region). 
ACTIVIT Y BRIEF

HOW THE DATA ARE BEING COLLECTED
Pre-and post-PPMV training surveys
The PPMVs complete pre-and post-training surveys to ascertain changes in knowledge and practices related to injectable contraceptives. Additionally, follow-up surveys are administered three, and nine months post-training to assess the PPMVs' practices, knowledge and skills over time.
Monitoring/supervision of PPMVs
Teams of study investigators, FMOH, SMOH, LGA officials and PCN monitor activities of trained PPMVs through followup meetings to identify and resolve implementation issues.
The monitoring visits will track progress, challenges, and successes of implementation, as well as gather information on clients' experience of adverse events. Involvement of the ministry stakeholders will also help them to see firsthand the PPMVs' abilities with administration of injectables and potentially help with eventual policy change.
Client exit interviews and surveys
To obtain female clients' perspectives, the researchers conduct exit interviews with progestin-only injectable contraceptive users who receive services from trained PPMVs. These users are also contacted for surveys at three, six, and nine months after their initial visit, enabling the assessment of continuation rates of progestin-only injectable contraceptive methods.
FOSTERING RESEARCH UTILIZATION
The research team has from the beginning of the study and will continue to engage key decision makers, such as the FMOH, SMOH and LGA health officials; utilize technical working groups to discuss emerging findings and lessons as the study progresses; and identify champions to promote the study findings to key stakeholders, such as health officials, NAPPMED, Pharmacy Council of Nigeria, FMOH, donors, NGOs, and so forth. In addition to regular meetings throughout the study to keep stakeholders informed of the progress and initial findings, a national dissemination meeting will be held with the key stakeholders to review and interpret the results and identify how they can be translated into policy. State-level meetings also will be held to share implementation successes and challenges related to PPMV delivery of injectable contraceptive services. 
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Injectable Contraceptive Methods
There are two types of injectable hormonal contraceptives: those that are injected intramuscularly, like Depo Provera, and those that are injected subcutaneously, like Sayana® Press. In Nigeria, intramuscular injections were the only available option for women wishing to use injectable contraception until 2014, when Sayana® Press was introduced as a second safe and efficacious option. Sayana® Press comes as a single dose in a prefilled, sterile syringe, and is administered once every three months. It is packaged in the Uniject injection system with an autodisposable device that eliminates the need to prepare a needle and syringe. Because the injection is subcutaneous, the needle is smaller and thus less painful.
